TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Universita Degli Studi Di Milano
Universita Degli Studi Di Milano
Affinity DataKi: 25nM ΔG°: -43.1kJ/mole IC50: 460nMpH: 7.5 T: 2°CAssay Description:Fluorescence polarization was measured on an Ultra plate reader (Tecan) at excitation and emission wavelengths of 485 and 530 nm, respectively. The e...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Universita Degli Studi Di Milano
Universita Degli Studi Di Milano
Affinity DataKi: 61nM ΔG°: -40.9kJ/mole IC50: 530nMpH: 7.5 T: 2°CAssay Description:Fluorescence polarization was measured on an Ultra plate reader (Tecan) at excitation and emission wavelengths of 485 and 530 nm, respectively. The e...More data for this Ligand-Target Pair
Affinity DataIC50: 0.110nMAssay Description:Displacement of [125I]-echistatin from alpha-v-beta-5 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 0.130nMAssay Description:Displacement of [125I]-echistatin from alpha-v-beta-5 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 0.590nMAssay Description:Displacement of [125I]-echistatin from alpha-v-beta-5 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant epitope-tagged JAK2 (808 to 1132) (unknown origin) using LPLDKDYYVVREPGQ as substrate by beta-countiing analysis in presenc...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant epitope-tagged JAK2 (808 to 1132) (unknown origin) using LPLDKDYYVVREPGQ as substrate by beta-countiing analysis in presenc...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant epitope-tagged JAK2 (808 to 1132) (unknown origin) using LPLDKDYYVVREPGQ as substrate by beta-countiing analysis in presenc...More data for this Ligand-Target Pair
Affinity DataIC50: 1.16nMAssay Description:Displacement of [125I]-echistatin from alpha-v-beta-5 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:Displacement of [125I]-echistatin from alphavbeta3 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:Displacement of [125I]-echistatin from alphavbeta3 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant epitope-tagged JAK2 (808 to 1132) (unknown origin) using LPLDKDYYVVREPGQ as substrate by beta-countiing analysis in presenc...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3.43nMAssay Description:Displacement of [125I]-echistatin from alpha-v-beta-5 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 4.56nMAssay Description:Displacement of [125I]-echistatin from alpha-v-beta-5 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 4.60nMAssay Description:Displacement of [125I]-echistatin from alphavbeta3 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 5.60nMAssay Description:Displacement of [125I]-echistatin from alphavbeta3 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 6.56nMAssay Description:Displacement of [125I]-echistatin from alpha-v-beta-5 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 7.20nMAssay Description:Displacement of [125I]-echistatin from alphavbeta3 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 7.70nMAssay Description:Displacement of [125I]-echistatin from alphavbeta3 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant epitope-tagged JAK2 (808 to 1132) (unknown origin) using LPLDKDYYVVREPGQ as substrate by beta-countiing analysis in presenc...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant epitope-tagged JAK2 (808 to 1132) (unknown origin) using LPLDKDYYVVREPGQ as substrate by beta-countiing analysis in presenc...More data for this Ligand-Target Pair
Affinity DataIC50: 9.93nMAssay Description:Displacement of [125I]-echistatin from alphavbeta3 integrin receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Inhibition of recombinant epitope-tagged JAK2 (808 to 1132) (unknown origin) using LPLDKDYYVVREPGQ as substrate by beta-countiing analysis in presenc...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Inhibition of recombinant human JAK2 (808-1132 residues) using LPLDKDYYVVREPGQ as substrate by radiometric assay in presence of [33P]-gamma-ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 13.1nMAssay Description:Displacement of [125I]-echistatin from alpha-v-beta-5 integrin receptorMore data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair